Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

Inclusion Criteria:

* 1\) Histological confirmed prostatic carcinoma patient
* 2\) Hormone non-respondence ex1) Although treatment PSA ≥ 5ng/ml ex2) PSA level were measured two times ex3) Prior one year radiology were processed
* 3\) Just 18 years over
* 4\) Has a score ≤1 on the ECOG Performance Scale
* 5\) Expected survival life time ≥ 6month
* 6\) Adequate bone marrow function hemoglobin ≥ 10.0g/dL , leukocyte count ≥ 4,000/mm3 thrombocyte ≥ 100,000/mm3
* 7\) Adequate blood coagulation function PT(INR) \< 1.5, aPTT\< 1.5 x control
* 8\) Adequate kidney function Normal blood upper level Creatinine ≤ 1.5 times
* 9\) Adequate liver function Normal blood upper level AST/ALT ≤ 1.5 times
* 10\) Autoimmune antibody system don't have disorder ex) anti-nuclear antibody, anti-thyroglobulin antibody negativity
* 11\) Person who didn't treat prior 6 weeks operation, radiotherapy treatment,immunotherapy or chemotherapy
* 12\) Patient who voluntarily participated clinical trial and confirmed a written consent

Exclusion Criteria:

* 1\) Having other malignancy or previous history of malignancy
* 2\) Brain metastases patient
* 3\) Having autoimmune disease or its history
* 4\) Pyrexia, rigor, leukocytosis infectious disease
* 5\) HBsAg, anti-HCV, HIV positive patient
* 6\) Myocardial infarction, cardiac insufficiency, other severe heart disease and non-controlled hypertension
* 7\) Severe and active medical disease
* 8\) Mental history disease or epilepsy
* 9\) Patients participated other clinical trial within 4 weeks
* 10\) Patients impossible to participate this trial by investigator's decision
* 11\) Patients who received immunosuppressant such as steroid, cyclosporin A, azathioprine within 6 weeks